The patient impact

Equaly’s vision is patient-centric; we aim to develop therapies accessible to everyone, bringing equality to healthcare systems around the world. We also want to provide patients with solutions that cure their disease, rather than just alleviating symptoms.

These goals mean we bring the patients themselves into the process. Nobody has a higher stake in the development of needed therapies than the patients and their loved ones. This is why we work with patient organizations and other groups to ensure that our translational efforts are in line with people’s needs.

Together with our partners, we are developing curative treatments for the following patient groups:

  • Patients being treated with biologicals for a gene defect (e.g. hemophilia A) or a chronic inflammatory disease (e.g. rheumatoid arthritis)

  • Patients considered for gene therapy or gene editing using viral vectors

  • Patients suffering from a chronic infection with an intracellular pathogen (e.g. Tuberculosis)

  • Patients affected by cancer

  • Patients affected by a tissue-specific chronic autoimmune disease (e.g. insulin-dependent diabetes or multiple sclerosis)

If you belong to any of these patient groups, please get in touch with us personally or through your patient organization